Drug Approval | November 21, 2023
GSK receives positive CHMP opinion recommending momelotinib for myelofibrosis patients with anaemia
Decision on EU marketing authorisation expected for momelotinib by early 2024
Decision on EU marketing authorisation expected for momelotinib by early 2024
Phase 3 data expected in the second half of 2024
Expanded collaboration with Vanguard Renewables aims to significantly increase the productivity of US renewable natural gas generation
General Medicine grows 5% and Vaccines 10% led by Shingrix
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Total transaction value of the divestment is Rs. 3,660 million
Biologics manufacturing to expand the Aragen platform by offering “gene to GMP” solution
Investment is additive to KKR’s existing health care growth strategy
Punit has more than 20 years of experience in the generics and branded pharmaceutical marketplace
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
Subscribe To Our Newsletter & Stay Updated
